William Blair Investment Management LLC trimmed its stake in Zoetis Inc (NYSE:ZTS) by 27.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,214,832 shares of the company’s stock after selling 1,213,155 shares during the period. Zoetis comprises about 0.9% of William Blair Investment Management LLC’s investment portfolio, making the stock its 22nd largest position. William Blair Investment Management LLC owned 0.66% of Zoetis worth $231,596,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors also recently made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. bought a new stake in Zoetis in the fourth quarter valued at $108,000. We Are One Seven LLC bought a new stake in Zoetis in the fourth quarter valued at $120,000. Premia Global Advisors LLC bought a new stake in Zoetis in the fourth quarter valued at $122,000. Icon Wealth Partners LLC bought a new stake in Zoetis in the fourth quarter valued at $127,000. Finally, Steward Partners Investment Advisory LLC bought a new stake in Zoetis in the third quarter valued at $114,000. Hedge funds and other institutional investors own 92.29% of the company’s stock.
In other Zoetis news, insider Heidi C. Chen sold 7,383 shares of the stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $84.71, for a total value of $625,413.93. Following the transaction, the insider now owns 20,162 shares of the company’s stock, valued at $1,707,923.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Roxanne Lagano sold 35,663 shares of the stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $81.02, for a total value of $2,889,416.26. Following the completion of the transaction, the executive vice president now directly owns 49,919 shares in the company, valued at approximately $4,044,437.38. The disclosure for this sale can be found here. Insiders sold 112,952 shares of company stock worth $9,219,843 in the last three months. Insiders own 0.31% of the company’s stock.
ZTS stock traded up $0.18 during trading hours on Wednesday, reaching $84.84. The company’s stock had a trading volume of 178,734 shares, compared to its average volume of 2,800,439. Zoetis Inc has a 1 year low of $52.25 and a 1 year high of $85.54. The company has a quick ratio of 2.55, a current ratio of 3.85 and a debt-to-equity ratio of 2.77. The firm has a market capitalization of $40,348.84, a price-to-earnings ratio of 48.38, a price-to-earnings-growth ratio of 1.87 and a beta of 0.97.
Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 15th. The company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.03. Zoetis had a return on equity of 65.96% and a net margin of 16.28%. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same quarter in the prior year, the firm posted $0.47 earnings per share. The company’s quarterly revenue was up 14.3% on a year-over-year basis. sell-side analysts expect that Zoetis Inc will post 3.04 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, April 20th will be paid a $0.126 dividend. This represents a $0.50 annualized dividend and a yield of 0.59%. The ex-dividend date is Thursday, April 19th. Zoetis’s payout ratio is 28.57%.
ZTS has been the topic of a number of analyst reports. Jefferies Group reiterated a “buy” rating and issued a $89.00 price target on shares of Zoetis in a research report on Tuesday, January 16th. Citigroup upgraded Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 target price on the stock in a report on Thursday, January 4th. Craig Hallum restated a “buy” rating and set a $85.00 target price (up previously from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd. Cantor Fitzgerald set a $85.00 target price on Zoetis and gave the stock a “buy” rating in a report on Tuesday, January 2nd. Finally, Piper Jaffray Companies restated a “buy” rating and set a $86.00 target price on shares of Zoetis in a report on Thursday, January 18th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have issued a buy rating to the stock. Zoetis has an average rating of “Buy” and a consensus target price of $79.72.
TRADEMARK VIOLATION WARNING: This report was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://ledgergazette.com/2018/03/21/william-blair-investment-management-llc-has-231-60-million-holdings-in-zoetis-inc-zts.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.